Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ   US4781601046

JOHNSON & JOHNSON (JNJ)

273
Delayed Quote. Delayed Nyse - 03/05 04:00:49 pm
102.52 USD   +0.86%
01:21a AbbVie in $21bn acquisition of cancer drug firm
03/05 JOHNSON & JOHNS : Local woman wins $5.7 million in lawsuit against J..
03/05DJBiotech Bidding War Yields Rich Price
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

05/17/2012 | 01:41pm US/Eastern
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

React to this article
Latest news on JOHNSON & JOHNSON
03:19a JOHNSON & JOHNSON : Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces..
01:21a AbbVie in $21bn acquisition of cancer drug firm
03/05 JOHNSON & JOHNSON : Local woman wins $5.7 million in lawsuit against Johnson & J..
03/05DJBiotech Bidding War Yields Rich Price
03/05 AbbVie CEO defends Pharmacyclics deal to sceptical investors
03/05DJAbbVie to Buy Pharmacyclics in $21 Billion Deal -- 4th Update
03/05 AbbVie CEO says new form of Humira could thwart generics
03/05 AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal
03/05DJAbbVie to Buy Pharmacyclics in $21 Billion Deal -- 3rd Update
03/05 DOW MOVERS : Cat, wmt
Advertisement
Chart
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF